Anticoagulation and compression therapy for proximal acute deep vein thrombosis

Area of Science:

• Vascular Medicine
• Pharmacology

Background:

• Proximal deep vein thrombosis (DVT) management involves distinct treatment phases: initial (1-3 weeks), primary (≥3 months), and secondary (beyond 3-6 months).
• Outpatient management is feasible for most DVT patients during the initial phase, with specific exclusion criteria for hospitalization.

Purpose of the Study:

• To outline the current treatment strategies for proximal deep vein thrombosis (DVT) of the lower limbs.
• To highlight the role of anticoagulants, particularly direct oral anticoagulants (DOACs), in DVT management.
• To discuss factors influencing anticoagulant choice and the use of elastic compression stockings (ECS).

Main Methods:

• Review of current treatment guidelines and pharmacological options for proximal DVT.
• Analysis of anticoagulant classes, including parenteral (heparin) and oral agents (VKA, DOACs).
• Consideration of patient-specific factors (renal/liver function, comorbidities) and adjunctive therapies like ECS.

Main Results:

• Direct oral anticoagulants (DOACs) are recommended as first-line therapy for proximal DVT, with no specific DOAC preference.
• Indefinite anticoagulation is advised for unprovoked DVT and patients with permanent risk factors.
• Low-dose apixaban and rivaroxaban are options for secondary DVT prevention; ECS aid in managing venous hypertension and edema.

Conclusions:

• DOACs represent the primary treatment for proximal DVT, offering flexibility in outpatient management.
• Treatment duration should be individualized, with extended anticoagulation indicated for specific patient groups.
• Elastic compression stockings serve as an adjunct therapy to mitigate DVT sequelae.